Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 601 AL 615

The Applications of CircRNA in the Diagnosis and Treatment of Alzheimer's Disease

Wen X, Huang C, Xie H, Hu D, Luo J, Li K.

Mol Neurobiol. 2024 Sep;61(9):6501-6510. doi: 10.1007/s12035-024-03977-0. Epub 2024 Feb 5.

New horizons in the diagnosis and management of Alzheimer's Disease in older adults

Dolphin H, Dyer AH, Morrison L, Shenkin SD, Welsh T, Kennelly SP.

Age Ageing. 2024 Feb 1;53(2):afae005. doi: 10.1093/ageing/afae005.

Adjunctive silymarin supplementation and its effects on disease severity, oxidative stress, and inflammation in patients with Alzheimer's disease

Navabi SM, Elieh-Ali-Komi D, Afshari D, Goudarzi F, Mohammadi-Noori E, Heydari K, Heydarpour F, Kiani A.

Nutr Neurosci. 2024 Oct;27(10):1077-1087. doi: 10.1080/1028415X.2023.2301163. Epub 2024 Feb 14.

Alzheimer's Disease: A Suitable Case for Treatment with Precision Medicine?

Pauwels EKJ, Boer GJ.

Med Princ Pract. 2024;33(4):301-309. doi: 10.1159/000538251. Epub 2024 Mar 25.

Self-Modulation of Gamma-Band Synchronization through EEG-Neurofeedback Training in the Elderly

Andrade K, Houmani N, Guieysse T, Razafimahatratra S, Klarsfeld A, Dreyfus G, Dubois B, Vialatte F, Medani T.

J Integr Neurosci. 2024 Mar 21;23(3):67. doi: 10.31083/j.jin2303067.

Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease

Singh N, Sharma S, Ghosh KK, Gupta B, Kuca K.

Curr Top Med Chem. 2024;24(13):1120-1133. doi: 10.2174/0115680266292514240404040341.

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review

Oosthoek M, Vermunt L, de Wilde A, Bongers B, Antwi-Berko D, Scheltens P, van Bokhoven P, Vijverberg EGB, Teunissen CE.

Alzheimers Res Ther. 2024 Apr 27;16(1):93. doi: 10.1186/s13195-024-01456-1.

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit.

JAMA Neurol. 2024 Jun 1;81(6):582-593. doi: 10.1001/jamaneurol.2024.0991.

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, Longo FM, Börjesson-Hanson A, Windisch M, Schmitz TW.

Nat Med. 2024 Jun;30(6):1761-1770. doi: 10.1038/s41591-024-02977-w. Epub 2024 May 17.

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease

Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, Wischik CM.

Transl Neurodegener. 2024 May 21;13(1):25. doi: 10.1186/s40035-024-00417-w.

GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review

Abubakar M, Nama L, Ansari MA, Ansari MM, Bhardwaj S, Daksh R, Syamala KLV, Jamadade MS, Chhabra V, Kumar D, Kumar N.

Curr Top Med Chem. 2024;24(19):1635-1664. doi: 10.2174/0115680266293416240515075450.

The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease

Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, Bottlaender M, Dorothée G.

Nat Aging. 2024 Jun;4(6):761-770. doi: 10.1038/s43587-024-00630-2. Epub 2024 Jun 5.

Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy

Sheng L, Bhalla R.

Neurochem Res. 2024 Sep;49(9):2273-2302. doi: 10.1007/s11064-024-04178-w. Epub 2024 Jun 6.

Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease

Taylor J, Jaros M, Chen C, Harrison J, Hilt D.

J Alzheimers Dis. 2024;100(1):139-150. doi: 10.3233/JAD-231456.

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease

Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, Sheardova K, Kesslak P, Shen L, Zhu X, Albayrak A, Paul J, Schaefer JF, Power A, Tolar M.

Drugs. 2024 Jul;84(7):811-823. doi: 10.1007/s40265-024-02067-8. Epub 2024 Jun 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias